Argus Research Maintains Buy on Eli Lilly and Co, Raises Price Target to $840
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst David Toung has maintained a Buy rating on Eli Lilly and Co (LLY) and increased the price target from $770 to $840.
May 14, 2024 | 4:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research's analyst David Toung has reaffirmed a Buy rating on Eli Lilly and Co, raising the price target from $770 to $840, indicating a positive outlook on the stock.
The increase in the price target by Argus Research suggests a strong confidence in Eli Lilly's future performance. Such endorsements from reputable analysts typically lead to positive short-term price movements as they reflect expectations of strong future performance and financial health of the company.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100